Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibody drug targets Hard-to-Treat blood cancers

NCT ID NCT06542250

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 4 times

Summary

This study tests an experimental drug called AZD5492 in people with B-cell cancers (like lymphoma or leukemia) that have come back or not responded to at least two prior treatments. The drug works by helping the body's T cells attack cancer cells. The trial will check safety, side effects, and whether the drug shrinks tumors. About 174 adults will take part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AZD5492 (a T-cell engaging antibody targeting CD20)
What this could lead to
If successful, this could provide a new treatment option for people with B-cell cancers that have not responded to other therapies.
What could go wrong
This is an early-phase trial, so safety and effectiveness are not yet proven. Side effects, including immune reactions, are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 174 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥18 years of age; * Histologically documented CD20+ mature B-cell neoplasm * Large B-cell lymphoma * Follicular lymphoma * Mantle cell lymphoma * Chronic lymphocytic leukemia * Small lymphocytic lymphoma * Relapsed, progressive and/or refractory disease following at least 2 prior lines of therapy; * ECOG performance status of ≤ 2 (\< 2 in EU countries). The above is a summary, other inclusion criteria details may apply. Exclusion Criteria: * Any neoplasm histology not specified in the IC section; * Active CNS involvement in lymphoma; * CNS pathology including but not limited to any history of seizure disorder/epilepsy; * Prior allogeneic HSCT within 180 days, prior autologous HSCT within 90 days, or cell therapy within 90 days of start of therapy; * History of Grade ≥ 3 CRS or Grade ≥ 3 ICANS; * Active and uncontrolled infections; * Unresolved AEs ≥2 Grade due to prior anticancer therapies, with some exceptions The above is a summary, other exclusion criteria details may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B cell malignancies are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia B-cell neoplasm follicular lymphoma large B-cell lymphoma Leukemia, B-Cell mantle cell lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B cell malignancies

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    30 sites in 10 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    RECRUITING

    La Jolla, California, 92093, United States

  • Research Site

    WITHDRAWN

    Boston, Massachusetts, 02215, United States

  • Research Site

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • Research Site

    RECRUITING

    Hackensack, New Jersey, 07601, United States

  • Research Site

    RECRUITING

    New York, New York, 10021, United States

  • Research Site

    RECRUITING

    New York, New York, 10029, United States

  • Research Site

    RECRUITING

    Charlotte, North Carolina, 28203, United States

  • Research Site

    RECRUITING

    Winston-Salem, North Carolina, 27157, United States

  • Research Site

    RECRUITING

    Houston, Texas, 77030, United States

  • Research Site

    RECRUITING

    Seattle, Washington, 98109, United States

  • Research Site

    RECRUITING

    Melbourne, 3000, Australia

  • Research Site

    RECRUITING

    Nedlands, 6009, Australia

  • Research Site

    RECRUITING

    Calgary, Alberta, T2N 5G2, Canada

  • Research Site

    RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

  • Research Site

    RECRUITING

    Montreal, Quebec, H3T 1R2, Canada

  • Research Site

    RECRUITING

    Hangzhou, 310003, China

  • Research Site

    RECRUITING

    Shanghai, 200025, China

  • Research Site

    RECRUITING

    København Ø, 2100, Denmark

  • Research Site

    RECRUITING

    Pessac, 33604, France

  • Research Site

    RECRUITING

    Villejuif, 94805, France

  • Research Site

    NOT_YET_RECRUITING

    Göttingen, DE-37099, Germany

  • Research Site

    RECRUITING

    München, 81675, Germany

  • Research Site

    RECRUITING

    Ulm, 89081, Germany

  • Research Site

    RECRUITING

    Würzburg, 97080, Germany

  • Research Site

    RECRUITING

    Bologna, 40138, Italy

  • Research Site

    RECRUITING

    Milan, 20133, Italy

  • Research Site

    RECRUITING

    Chūōku, 104-0045, Japan

  • Research Site

    RECRUITING

    Kashiwa, 277-8577, Japan

  • Research Site

    RECRUITING

    Barcelona, 08035, Spain

  • Research Site

    RECRUITING

    L'Hospitalet de Llobregat, 08908, Spain

  • Research Site

    RECRUITING

    Madrid, 28040, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.